- Trials with a EudraCT protocol (86)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
86 result(s) found for: Qualified Person.
Displaying page 1 of 5.
EudraCT Number: 2004-004602-25 | Sponsor Protocol Number: M04-716 | Start Date*: 2005-06-30 |
Sponsor Name:Abbott GmbH & Co. KG | ||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind,Double-Dummy, Placebo-Controlled StudyComparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects withModerate to Severe... | ||
Medical condition: Psoriasis Disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) BE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-004117-40 | Sponsor Protocol Number: Q03.13.01 | Start Date*: 2013-12-19 |
Sponsor Name:Fidia Farmaceutici SpA | ||
Full Title: Randomized, controlled, double-blinded clinical trial, with open-label extension on the efficacy of ultrasound guided injection of hyaluronic acid (500-730 KDa) (HYALGAN®) versus saline solution in... | ||
Medical condition: Achilles tendinopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020063-21 | Sponsor Protocol Number: ILUVIT1 | Start Date*: 2010-06-15 | |||||||||||
Sponsor Name:Charité-Universitätsmedizin | |||||||||||||
Full Title: “A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis” | |||||||||||||
Medical condition: Urticarial vasculitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003828-23 | Sponsor Protocol Number: ML39310 | Start Date*: 2017-04-11 | |||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin; Dpt. of Dermatology and Allergy | |||||||||||||
Full Title: A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS) | |||||||||||||
Medical condition: Schnitzler’s syndrome (SchS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005726-30 | Sponsor Protocol Number: CURES-IL1T-OT-1236 | Start Date*: 2014-04-28 |
Sponsor Name:Charité - Universitätsmedizin | ||
Full Title: A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU) | ||
Medical condition: cold contact urticaria (CCU) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003530-17 | Sponsor Protocol Number: C0743T09 | Start Date*: 2006-07-21 |
Sponsor Name:Centocor B.V. | ||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis | ||
Medical condition: Moderate to severe plaque psoriasis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) DE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004067-30 | Sponsor Protocol Number: CO168X94 (EU-116) | Start Date*: 2006-05-08 |
Sponsor Name:Department of Rheumatology, Internal Medicine III, Medical University of Vienna | ||
Full Title: A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFafa Chimeric Monoclonal Antibody (Infliximab, Remicade®) and Azathioprine in Patients Suffering from Systemic Lupus Ery... | ||
Medical condition: Systemic Lupus Erythematosus (SLE) with WHO Class V Glomerulonephritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-001608-35 | Sponsor Protocol Number: HUM-04-80 | Start Date*: 2006-12-01 | |||||||||||
Sponsor Name:Dr. Valérie gangji | |||||||||||||
Full Title: TREATMENT OF SCIATICA BY ADALIMUMAB INJECTION : A RANDOMIZED, DOUBLE BLIND CONTROLLED TRIAL. | |||||||||||||
Medical condition: To determine the efficacy of adalimumab in disc herniation-induced sciatica in a controlled randomised double blind pilot study. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004971-37 | Sponsor Protocol Number: STRU-09-06 | Start Date*: 2007-04-05 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: Adalimumab for psoriasis patients who are non-responders to etanercept: An open-label study | |||||||||||||
Medical condition: psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003746-41 | Sponsor Protocol Number: CIGE025EDE14T | Start Date*: 2012-01-12 | |||||||||||
Sponsor Name:Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihistamine-resistant cold contact urticari... | |||||||||||||
Medical condition: Cold contact urticaria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005615-87 | Sponsor Protocol Number: CIGE025EDE17T | Start Date*: 2012-11-06 | |||||||||||
Sponsor Name:Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled 12-week, parallel-group study with a 6 week follow up period to demonstrate efficacy and safety of subcutaneous Omalizumab in patients wi... | |||||||||||||
Medical condition: Urticaria factitia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000181-39 | Sponsor Protocol Number: C0168X84, EU-0108 | Start Date*: 2005-08-31 |
Sponsor Name:Med. Universitaetsklinik Graz, ao Univ. Professor Dr. med. Thomas C. Wascher | ||
Full Title: A Prospective Trial of Anti-TNF-a Chimeric Monoclonal Antibody (infliximab, Remicade®) on Insulin Sensitivity, Beta Cell Function and Cardiovascular Risk Profile in Insulin Resistant Human Obesity | ||
Medical condition: Insulin Resistant Human Obesity | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-008171-34 | Sponsor Protocol Number: CNTO1275PSO4004 | Start Date*: 2009-09-01 | |||||||||||
Sponsor Name:Janssen-Cilag EMEA Medical Affairs | |||||||||||||
Full Title: AN EXPLORATORY TRIAL TO ASSESS NATURALISTIC SAFETY AND EFFICACY OUTCOMES IN PATIENTS TRANSITIONED TO USTEKINUMAB FROM PREVIOUS METHOTREXATE THERAPY (TRANSIT) | |||||||||||||
Medical condition: moderate to severe plaque psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) AT (Completed) SE (Completed) BE (Completed) HU (Completed) LT (Completed) DK (Completed) FI (Completed) FR (Completed) SK (Completed) PT (Completed) ES (Completed) GB (Completed) BG (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007672-41 | Sponsor Protocol Number: Protocol B4Z-MC-LYDO | Start Date*: 2008-12-23 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Protocol B4Z-MC-LYDO(b) Maintenance of Response After Open-Label Treatment with Atomoxetine Hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Cont... | |||||||||||||
Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) DE (Completed) ES (Completed) FR (Completed) PT (Completed) SE (Completed) AT (Completed) FI (Completed) BE (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014567-39 | Sponsor Protocol Number: M10-883 | Start Date*: 2010-02-19 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Peripheral Spondyloarthritis | |||||||||||||
Medical condition: Peripheral Spondyloarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) BE (Completed) IE (Completed) HU (Completed) ES (Completed) CZ (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004290-97 | Sponsor Protocol Number: ACCILTRA1 | Start Date*: 2008-12-19 |
Sponsor Name:Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy | ||
Full Title: A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzle... | ||
Medical condition: The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-003444-30 | Sponsor Protocol Number: C0743T12 | Start Date*: 2007-05-15 | |||||||||||
Sponsor Name:Centocor B.V. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) BE (Completed) NL (Completed) GB (Completed) AT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004139-31 | Sponsor Protocol Number: M06-810 | Start Date*: 2007-04-03 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Period, Double − Blind Study to Determine the Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab Combination Therapy in Patients with Early... | |||||||||||||
Medical condition: Rheumatoid Arthritis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) SK (Completed) ES (Completed) AT (Completed) FR (Completed) SE (Completed) CZ (Completed) DE (Completed) NL (Completed) HU (Completed) NO (Completed) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-003298-10 | Sponsor Protocol Number: C0524T08 | Start Date*: 2006-06-07 |
Sponsor Name:Centocor BV | ||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Psoriatic Arthritis | ||
Medical condition: Psoriatic Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) GB (Completed) BE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002159-24 | Sponsor Protocol Number: 54861911ALZ2002 | Start Date*: 2014-10-27 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects in the Early (Predementia) Alzheime... | |||||||||||||
Medical condition: Early Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) SE (Completed) ES (Completed) NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
